Tracey L Mc Cain Blueprint Medicines Corp (BPMC) insider trading activity

Tracey L Mc Cain is EVP & Chief Legal Officer of Blueprint Medicines Corp. Currently has a direct ownership of 0 shares of BPMC, which is worth approximately $0. The most recent transaction as insider was on Jul 17, 2025, when has been sold 51,103 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Tracey L McCain Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 17 2025	SELL Sale (or disposition) back to the issuer	-	51,103 Reduced 57.94%	37,092 Common Stock
Jul 17 2025	SELL Disposition due to a tender of shares in a change of control transaction	-	37,092 Reduced 100.0%	0 Common Stock
Jul 17 2025	BUY Grant, award, or other acquisition	-	21,353 Added 19.49%	88,195 Common Stock
Mar 05 2025	SELL Open market or private sale	$467,265 $88.8 p/Share	5,262 Reduced 7.32%	66,583 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	11,000 Added 13.28%	71,845 Common Stock
Mar 07 2024	SELL Open market or private sale	$471,043 $90.69 p/Share	5,194 Reduced 7.91%	60,498 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	12,500 Added 15.99%	65,692 Common Stock
Mar 06 2023	SELL Open market or private sale	$149,722 $45.07 p/Share	3,322 Reduced 5.93%	52,666 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	12,500 Added 18.25%	55,988 Common Stock
Mar 07 2022	SELL Open market or private sale	$58,831 $56.19 p/Share	1,047 Reduced 2.36%	43,227 Common Stock
Mar 03 2022	SELL Open market or private sale	$100,487 $60.28 p/Share	1,667 Reduced 3.63%	44,274 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	12,500 Added 21.39%	45,941 Common Stock
Dec 07 2021	SELL Open market or private sale	$482,300 $96.46 p/Share	5,000 Reduced 13.01%	33,441 Common Stock
Dec 07 2021	BUY Exercise of conversion of derivative security	$141,800 $28.36 p/Share	5,000 Added 11.51%	38,441 Common Stock
Nov 03 2021	SELL Open market or private sale	$550,900 $110.18 p/Share	5,000 Reduced 13.06%	33,274 Common Stock
Nov 03 2021	BUY Exercise of conversion of derivative security	$141,800 $28.36 p/Share	5,000 Added 11.55%	38,274 Common Stock
Sep 23 2021	SELL Open market or private sale	$2,719,500 $108.78 p/Share	25,000 Reduced 42.9%	33,274 Common Stock
Sep 23 2021	BUY Exercise of conversion of derivative security	$709,000 $28.36 p/Share	25,000 Added 30.02%	58,274 Common Stock
Mar 04 2021	SELL Open market or private sale	$166,224 $87.81 p/Share	1,893 Reduced 5.45%	32,852 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	13,062 Added 27.32%	34,745 Common Stock

Also insider at

KNSA

Kiniksa Pharmaceuticals, Ltd. Healthcare

IMGN

ImmunoGen, Inc. Healthcare

Director

TLM

Tracey L Mc Cain

EVP & Chief Legal Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Value

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC

Account